Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Anniina Farkkila, Ph.D., M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Zhou J, Gelot C, Pantelidou C, Li A, Yücel H, Davis RE, Farkkila A, Kochupurakkal B, Syed A, Shapiro GI, Tainer JA, Blagg BSJ, Ceccaldi R, D'Andrea AD. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nat Cancer. 2021 Jun; 2(6):598-610. PMID: 34179826.
    Citations: 8     
  2. Crosley P, Farkkila A, Jenner AL, Burlot C, Cardinal O, Potts KG, Agopsowicz K, Pihlajoki M, Heikinheimo M, Craig M, Fu Y, Hitt MM. Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro. Int J Mol Sci. 2021 Apr 29; 22(9). PMID: 33946730.
    Citations:    Fields:    Translation:HumansCells
  3. Iyer S, Zhang S, Yucel S, Horn H, Smith SG, Reinhardt F, Hoefsmit E, Assatova B, Casado J, Meinsohn MC, Barrasa MI, Bell GW, Pérez-Villatoro F, Huhtinen K, Hynninen J, Oikkonen J, Galhenage PM, Pathania S, Hammond PT, Neel BG, Farkkila A, Pépin D, Weinberg RA. Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. Cancer Discov. 2021 02; 11(2):384-407. PMID: 33158843.
    Citations: 9     Fields:    
  4. Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG. TERT promoter mutation in adult granulosa cell tumor of the ovary. Mod Pathol. 2018 07; 31(7):1107-1115. PMID: 29449679.
    Citations: 10     Fields:    Translation:HumansCells
  5. Färkkilä A, Haltia UM, Tapper J, McConechy MK, Huntsman DG, Heikinheimo M. Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Ann Med. 2017 08; 49(5):435-447. PMID: 28276867.
    Citations: 16     Fields:    Translation:Humans
  6. Haltia UM, Andersson N, Yadav B, Färkkilä A, Kulesskiy E, Kankainen M, Tang J, Bützow R, Riska A, Leminen A, Heikinheimo M, Kallioniemi O, Unkila-Kallio L, Wennerberg K, Aittokallio T, Anttonen M. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. Gynecol Oncol. 2017 03; 144(3):621-630. PMID: 28104295.
    Citations: 9     Fields:    Translation:HumansCells
  7. Haltia UM, Hallamaa M, Tapper J, Hynninen J, Alfthan H, Kalra B, Ritvos O, Heikinheimo M, Unkila-Kallio L, Perheentupa A, Färkkilä A. Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors. Gynecol Oncol. 2017 Jan; 144(1):83-89. PMID: 27871721.
    Citations: 4     Fields:    Translation:Humans
  8. Färkkilä A, McConechy MK, Yang W, Talhouk A, Ng Y, Lum A, Morin RD, Bushell K, Riska A, McAlpine JN, Gilks CB, Unkila-Kallio L, Anttonen M, Huntsman DG. FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor. J Mol Diagn. 2017 01; 19(1):126-136. PMID: 27810330.
    Citations: 7     Fields:    Translation:HumansCells
  9. Bryk S, Färkkilä A, Bützow R, Leminen A, Tapper J, Heikinheimo M, Unkila-Kallio L, Riska A. Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors. Gynecol Oncol. 2016 Dec; 143(3):571-577. PMID: 27729108.
    Citations: 5     Fields:    Translation:Humans
  10. McConechy MK, Färkkilä A, Horlings HM, Talhouk A, Unkila-Kallio L, van Meurs HS, Yang W, Rozenberg N, Andersson N, Zaby K, Bryk S, Bützow R, Halfwerk JB, Hooijer GK, van de Vijver MJ, Buist MR, Kenter GG, Brucker SY, Krämer B, Staebler A, Bleeker MC, Heikinheimo M, Kommoss S, Blake Gilks C, Anttonen M, Huntsman DG. Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. J Natl Cancer Inst. 2016 11; 108(11). PMID: 27297428.
    Citations: 14     Fields:    Translation:Humans
  11. Färkkilä A, Zauli G, Haltia UM, Pihlajoki M, Unkila-Kallio L, Secchiero P, Heikinheimo M. Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors-implications for therapeutic potential. Tumour Biol. 2016 Sep; 37(9):11909-11916. PMID: 27067438.
    Citations:    Fields:    Translation:HumansCells
  12. Färkkilä A, Unkila-Kallio L. [Diagnosis and follow-up observation of granulosa cell tumor of the ovary are becoming more precise]. Duodecim. 2016; 132(11):1033-9. PMID: 27400589.
    Citations:    Fields:    Translation:Humans
  13. Färkkilä A, Laitinen L. [Heterotopic pregnancy during the second trimester is a severe complication of pregnancy]. Duodecim. 2016; 132(8):730-3. PMID: 27244932.
    Citations: 1     Fields:    Translation:Humans
  14. Pihlajoki M, Färkkilä A, Soini T, Heikinheimo M, Wilson DB. GATA factors in endocrine neoplasia. Mol Cell Endocrinol. 2016 Feb 05; 421:2-17. PMID: 26027919.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  15. Färkkilä A, Koskela S, Bryk S, Alfthan H, Bützow R, Leminen A, Puistola U, Tapanainen JS, Heikinheimo M, Anttonen M, Unkila-Kallio L. The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors--A comparative study with inhibin B. Int J Cancer. 2015 Oct 01; 137(7):1661-71. PMID: 25808251.
    Citations: 15     Fields:    Translation:Humans
  16. Bryk S, Färkkilä A, Bützow R, Leminen A, Heikinheimo M, Anttonen M, Riska A, Unkila-Kallio L. Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience. Int J Gynecol Cancer. 2015 Jan; 25(1):33-41. PMID: 25347095.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  17. Färkkilä A, Andersson N, Bützow R, Leminen A, Heikinheimo M, Anttonen M, Unkila-Kallio L. HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study. Cancer Med. 2014 Jun; 3(3):526-36. PMID: 24687970.
    Citations: 13     Fields:    Translation:Humans
  18. Andersson N, Anttonen M, Färkkilä A, Pihlajoki M, Bützow R, Unkila-Kallio L, Heikinheimo M. Sensitivity of human granulosa cell tumor cells to epidermal growth factor receptor inhibition. J Mol Endocrinol. 2014 Apr; 52(2):223-34. PMID: 24463098.
    Citations: 1     Fields:    Translation:HumansCells
  19. Anttonen M, Pihlajoki M, Andersson N, Georges A, L'hôte D, Vattulainen S, Färkkilä A, Unkila-Kallio L, Veitia RA, Heikinheimo M. FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells. PLoS One. 2014; 9(1):e85545. PMID: 24416423.
    Citations: 21     Fields:    Translation:HumansCells
  20. Färkkilä A, Pihlajoki M, Tauriala H, Bützow R, Leminen A, Unkila-Kallio L, Heikinheimo M, Anttonen M. Serum vascular endothelial growth factor A (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro. J Clin Endocrinol Metab. 2011 Dec; 96(12):E1973-81. PMID: 21994955.
    Citations: 7     Fields:    Translation:HumansCells
  21. Anttonen M, Färkkilä A, Tauriala H, Kauppinen M, Maclaughlin DT, Unkila-Kallio L, Bützow R, Heikinheimo M. Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis. Lab Invest. 2011 Nov; 91(11):1605-14. PMID: 21808236.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  22. Färkkilä A, Anttonen M, Pociuviene J, Leminen A, Butzow R, Heikinheimo M, Unkila-Kallio L. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors. Eur J Endocrinol. 2011 Jan; 164(1):115-22. PMID: 21041381.
    Citations: 15     Fields:    Translation:Humans
  23. Saaristo A, Tammela T, Farkkila A, Kärkkäinen M, Suominen E, Yla-Herttuala S, Alitalo K. Vascular endothelial growth factor-C accelerates diabetic wound healing. Am J Pathol. 2006 Sep; 169(3):1080-7. PMID: 16936280.
    Citations: 58     Fields:    Translation:HumansAnimals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Farkkila's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (137)
Co-Authors (8)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.